Integra LifeSciences (IART) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue reached $418.2 million, up 9.7% year-over-year and exceeding guidance, with 2.3% organic growth and 0.3% growth excluding Boston-related impacts.

• Adjusted EPS was $0.63, within guidance but down 11% from 2023; GAAP net loss was $12.4 million, driven by acquisition and higher manufacturing costs.

• Strong demand across the portfolio, early success integrating Acclarent, and progress on product relaunches highlighted operational achievements.

• Compliance Master Plan launched to address quality and operational gaps, leading to temporary shipping holds and impacting near-term revenue and earnings.

• Announced plans to restart PriMatrix and SurgiMend manufacturing at the Braintree facility in H1 2026; SurgiMend received PMA approvable notification pending GMP certification.

Financial highlights

• Q2 2024 revenue: $418.2 million (+9.7% year-over-year, ~$2M above guidance); organic growth 2.3%.

• Adjusted EPS $0.63, down 10.6% year-over-year; adjusted EBITDA margin 20.0%, down 330bps.

• GAAP gross margin was 54.0% (down from 54.3%); adjusted gross margin 65.2% (down 250–290bps year-over-year).

• Operating cash flow for Q2 was $40.4 million; free cash flow $10.7 million; adjusted free cash flow conversion 21.8%.

• Net debt at June 30 was $1.54 billion; total liquidity stood at ~$1.18 billion, including $297 million in cash.

Outlook and guidance

• Full-year 2024 revenue guidance: $1.609–$1.629 billion (4.4%–5.7% reported growth, –1.0% to 0.3% organic); adjusted EPS: $2.41–$2.57.

• Q3 2024 revenue expected at $372–$382 million (–2.6% to 0.0% reported, –9.4% to –6.7% organic); adjusted EPS $0.36–$0.44.

• Full-year organic growth expected between –1% and +0.3%.

• 2025 outlook: mid-single-digit organic revenue growth, but flat to modest adjusted EPS growth due to ongoing compliance investments.

• Guidance reflects temporary shipping holds and increased investment in quality and compliance, with most holds expected to be released by end of Q3.